

Aleck H Alexopoulos

Senior Research Scientist, CPERI

Co-founder of RespiBit Ltd

CERTH, 6th km. Harilaou-Thermi road, Box 60361,  
Thermi, Thessaloniki 57001, Greece

E-mail: [aleck@certh.gr](mailto:aleck@certh.gr)

W: +30 2310 498 168

M: +30 6936149137



Aleck H. Alexopoulos [aleck@certh.gr](mailto:aleck@certh.gr) +30 2310498168  
Chemical Engineer → Biomedical Engineer → Entrepreneur



Diploma - AUTH Chemical Eng.  
PhD - Purdue University  
Postdoc - MIT

Rheology of dense  
dispersions in solid  
rocket fuels

Free surface flows  
of complex fluids  
and liquid crystals

### Expertise, Activities, and Interests

#### As CERTH:

Computational support to LPRE/CPERI/CERTH activities  
Fluid mechanics (non-Newtonian, complex fluids, dispersions ,etc.)  
Interfacial Mechanics (static/dynamic,, emulsions, suspensions, etc.)  
Complex flows (dense dispersion, free-surface flows, micro-flow)  
Polymer reaction Engineering (emulsion, dispersion, suspension)  
Population Balance Models (dispersions and beyond, compartment models, with CFD, etc.)  
Respiratory System studies (drug delivery, virtual twin, deposition)  
Biodevices (dry powder inhalers)




#### Main interests today at CERTH:

Applications of **human movement** algorithms for functional capacity: rehab, ND disease, etc.  
Next generation of **pandemic models** incorporating aerosol transmission: populations, transport hubs  
**Virtual Twin** of Lungs (drug delivery, next gen ventilators, personalized treatment)

#### As RespiBit:

Digital Health (**AsthmaFit**: asthma management system) for asthma patients, municipalities, pharma  
Medical devices (**TBscan**: tuberculosis mycobacterium detection via breath analysis)  
**Drone system** for determination of concentration plus rate of transfer: environmental, sustainability, etc.





Pilot Plants

Incubator

Admin

# 1. Human Movement Models and Applications

Originally developed for evaluation of athletes in turn of movement capacity. And for the determination of truly personalized and optimal training programs.

Several applications beyond sports:

- Rehabilitation


- Muscle wasting

- Patient evaluation and classification (together with other digital tools)

- Post-surgery Recovery

- Pre-surgery Evaluation

- Deep monitoring of ND disease




+ 25%

*Democritus University Thrace, Greece  
Human Performance Lab  
Dr. Thanasis Chatzinikolaou*




DEMOCRITUS  
UNIVERSITY  
OF THRACE

*DUTH University Trial:  
15 student athletes, @4 weeks  
when compared to a traditional program  
Ergo produced +26% on average  
(up to +79% ) increase in strength*



## Some medical applications – Functional Capacity

- Muscle wasting monitoring + minimization, e.g., disease-associated, microgravity
- Rehabilitation monitoring + minimization / patient stratification, “art” → “science”
- Post-surgery Recovery monitoring + management to achieve rapid and full recovery
- Pre-surgery Evaluation for sarcopenia or frailty / improved outcomes
- Deep monitoring of ND disease early diagnosis / exacerbation detection / management



## Enhanced movement applications:

EU proposal on exoskeleton



AFFOA David Fink smart fabrics



This single, elastic fiber contains a series of microdevices, including sensors, a microcontroller, digital memory, bluetooth modules, optical communications, and a battery, making up all the necessary components of a computer. An operating fiber computer shown knotted (left) and hanging with a 1-kilogram weight attached (right). (Courtesy Nikhil Gupta/Fink Lab MIT)

Hugh Herr: soft-robotics





# Movement/Stress Connection in Multiple Sclerosis


**Daily evaluations**

*Wrist wearable*

- Accelerometer
- Pulse rate
- Skin conductivity
- Muscle Activation Sensor Suit, MASS
- Multi-point EMG

• Drug regiment

• Symptoms




**AI Models**

Recursive Neural Net

Regression

Global AI



**Weekly evaluations**

*Stress evaluation*


- Questionnaires
- Response tests

*Movement tests*

- Questionnaires
- Response tests

*Biological Data*

- Inflammation status or other



**Final Outputs**




Stress profile

Neuromuscular status

Disease/Wellness status

Next day/week projections


Pharmaceutical/Activity interventions

-  Literature open models → sub-types of stress
-  Dynamic kinetic chains = Ergo algorithms
-  Muscle synergy models

# Respiratory System Simulations: Application to a Dry Powder Inhaler



# Background Technology: CFD / particle model




First dynamic particle simulation in the nasal cavity during dynamic inhalation

First dynamic particle simulation in the alveoli during multiple inhalations

Strictly Confidential

# Background Technology: CFD Dry Powder Inhalers

Turbuhaler®




Validation – First ever prediction of emitted dose and fine particle fraction for a commercial DPI

Mechanisms described:

- Powder fluidization (empirically or DEM)
- Collision with walls
- Deposition on walls
- Collisional breakage

Determined properties:

- Pressure drop
- Flow patterns
- Depositions
- Outlet particulate flow




# Background Technology: CFD Outflow dynamics from DPI

Instantaneous outflow of particles from a DPI device and instantaneous deposition of particles within the device during a dynamic inhalation from a commercial DPI (Tubuhaler©).

## Effect of inhalation dynamics!

First results of this type ever published





- ✓ PIFR - Peak Inspiratory Flow Rate
- ✓ FIR – Flow Increase Rate

$$Q = PIFR(1 - e^{-\alpha t})$$

$$\alpha = 2.31FIR/PIFR$$

- ✓  $a = 5.31$ , slow FIR = 2.3 l/s<sup>2</sup>
- ✓  $a = 18.46$ , fast FIR = 8.1 l/s<sup>2</sup>




Strictly Confidential





# Background Technology: Optimization of a DPI Device

Three geometries are compared




Velocity Magnitude





Deposited Particles  
Q = 30L/min

Depositional Loss



FPF




Q = 70L/min

# Background Technology: Compartment Models of Powder Processes


Point of this unique technology is that we can perform full simulations within seconds instead of hours/days of CFD time.

- Compartment models are developed to describe the particle size distribution, PSD, as a function of time in a small number ( $N \ll N_{CFD} \sim 10^6$ ) of compartments.
- This approach permits the description of dynamic PSD including effects of breakage/aggregation, deposition/re-dispersion.




Compartment exchange flow rates,  $Q_i$ ,  $Q_{i-1}$ , energy dissipation rates  $\varepsilon_i$ , and the compartment particle-wall collision and deposition rates are obtained from the CFD solution.

Effect of breakage rate – Consistency check with CFD model



Improved results for FPF



Compartment model is consistent to the CFD-particle model and can be used to describe additional phenomena.

# Virtual Lung

Whole lung mechanics

From air-flow (CFD, 1D, 2D, 3D models) and deposition models

from oral and nasal cavities (and devices) down to alveoli

To mucous layer interaction (penetration, entrainment, dissolution, swelling, drug release)

Surfactant layer interaction (at alveoli and terminal bronchiole)

To biological interactions (at the mucous layer, epithelial layers)

and physicochemical (oxidative stress, reactivity)

To biological response (e.g., inflammation, cytokine activation)

and immune system response

Multi-scale in length and time

Multi-model with many unknowns

Integration is problematic

Need a combined data-based + computational model output to develop a digital twin

## Cystic Fibrosis

- Mucous layer model, clearance and local dynamics. Very important to understand how mucolytic drugs should be targeted. Improper targeting can make matters worse!
- Mucous layer rheology is non-Newtonian in nature and affected by mucolytics.
- Mucous layer models can be combined with pulmonary models for intelligent drug delivery.
- Largely unsolved problem today

### Also

- Exacerbations of symptoms in people with cystic fibrosis can probably be predicted with the system used by RespiFit (monitor exposure/symptom histories and deep AI)